Research & Patents
Breakthrough research in antibiotic development, addressing critical challenges in multidrug-resistant bacterial infections through innovative molecular design and medicinal chemistry.
Modified Carbapenem Antibiotics with Improved Activity Against KPC Carbapenemase-Producing Enterobacterales
Key Innovation
Restoring the power of carbapenems against even the most resilient KPC-producing pathogens through strategic molecular modifications that prevent enzymatic destruction while maintaining potent antibacterial activity.
US 20240383899 A1 • Published November 21, 2024
"Restoring the power of carbapenems against even the most resilient KPC-producing pathogens"
Mechanism & Innovation
- • Enzymatic-Hydrolysis Resistance: Molecular modifications prevent KPC carbapenemase from opening the β-lactam ring
- • Synergistic Compatibility: Fully compatible with existing β-lactamase inhibitors
- • Flexible Administration: Formulated for oral, IV, and alternative delivery routes
Performance Highlights
- • Laboratory Potency: Robust inhibition of KPC-producing strains with therapeutic MICs
- • Broad Spectrum: Coverage against key CRE species resistant to current carbapenems
- • Safety Profile: Favorable safety margin in preliminary cytotoxicity testing
Development Status
- • Laboratory validation completed
- • Proof-of-concept demonstrated
- • Ready for advanced in vivo studies
Market Opportunities
Hospital Infection Control
Integration into antimicrobial stewardship programs for high-risk wards (ICU, transplant units)
Pharmaceutical Partnerships
Licensing for co-development with established antibiotic manufacturers
Global Health Initiatives
Strategic deployment in regions facing escalating CRE outbreaks
Licensing & Collaboration
Opportunities available for exclusive or field-limited licensing with flexible deal structures to support various partnership models.
Ideal Partners
Companies with advanced clinical-development infrastructure and global distribution networks
Patent Details
Claims Coverage
Composition of matter for C-3-modified carbapenems exhibiting KPC resistance, plus associated methods of use and combination regimens.